Information Provided By:
Fly News Breaks for January 4, 2019
TTPH
Jan 4, 2019 | 14:20 EDT
B. Riley FBR analyst David Buck resumed coverage of Tetraphase Pharmaceuticals with a Buy rating and $3 price target.
News For TTPH From the Last 2 Days
There are no results for your query TTPH